Vitamin K: Role in Clotting and Bone — Interactions with Anticoagulants

Vitamin K role in clotting and bone is to enable gamma‑carboxylation of vitamin K–dependent proteins, supporting coagulation factors II, VII, IX and X plus osteocalcin; the U.S. Recommended Dietary Allowance is roughly 120 µg/day for adult men and 90 µg/day for adult women. Vitamin K exists primarily as phylloquinone (K1) from leafy greens and as menaquinones (K2) in fermented foods and some animal products. Hepatic vitamin K is critical for clotting factor activation, while extrahepatic K2 isoforms contribute to bone matrix carboxylation and vascular matrix protein function. Anticoagulant therapy, most notably warfarin, alters this balance and requires ongoing individualized monitoring by clinicians.

Mechanistically, vitamin K functions as a cofactor for gamma‑glutamyl carboxylase to carboxylate glutamate residues on clotting proteins, a cycle regenerated by vitamin K epoxide reductase (VKORC1); inhibition of VKORC1 by warfarin reduces gamma‑carboxylation and prolongs prothrombin time measured as INR. Laboratory tools such as the PT/INR assay and point‑of‑care INR devices quantify anticoagulant effect and guide dose adjustment. Clinical guidance on vitamin K and anticoagulants focuses on maintaining stable intake rather than complete restriction, especially when initiating or adjusting anticoagulation. The debate over phylloquinone vs menaquinone bioavailability influences dietary counseling, because K1 is concentrated in greens while K2 subforms vary in half‑life and tissue distribution, and patient education materials emphasize consistency.

A common misconception is that all vitamin K sources are interchangeable; phylloquinone and menaquinones differ in absorption, half‑life and tissue targeting, so conflating them misleads both nutrition counseling and research on vitamin K2 bone health. Clinicians should note that dietary change, not only pharmacologic antagonism, can produce clinically meaningful INR shifts: for example, increasing daily leafy‑green intake can lower INR toward subtherapeutic levels in a patient with a 2.0–3.0 target, while broad‑spectrum antibiotics that suppress gut menaquinone production have been associated with INR elevation and bleeding. Vitamin K deficiency bleeding remains a separate neonatal issue and does not justify unsupervised supplementation for anticoagulated adults. When supplementation is contemplated, pharmacogenetic testing for VKORC1 and CYP2C9 and close INR follow‑up are typically integrated into anticoagulation clinic practice. Supplements commonly vary.

Practically, clinicians and patients should prioritize a food‑first strategy emphasizing consistent intake of phylloquinone‑rich vegetables and consider K2 through diet rather than unsupervised supplements; any intentional change in vitamin K intake should be communicated to the anticoagulation team and documented in medication reconciliation. INR monitoring intervals may be shortened when diet or antibiotics change, and pharmacists can assist with reviewing over‑the‑counter supplements that contain vitamin K, and clinical follow‑up. For bone health discussions, focus on overall calcium, vitamin D status and evidence for menaquinone subforms rather than high‑dose empirical K supplementation. This page contains a structured, step‑by‑step framework.